바이오인

 

 

 

The Fifteenth International Molecular Medicine Tri-Conference delivered the hottest areas of biotechnology brought together in one location.  Molecular Diagnostics, Medicinal Chemistry, Stem Cells and Translational Medicine were the buzz at this year’s event.  The presenters delivered pragmatic and solution-driven insights that captivated the audience and the exhibit hall delivered more technologies than ever before.  Attendance hit historic levels reaching 2800 delegates for first time.  The continued growth of the event is a strong indicator that the confluence of biology, chemistry and business is being realized.

 

 

 

 

8:55 am Using Molecular Medicine to do Therapeutic Development in the Network Age
Jay M. Tenenbaum, Ph.D., Chairman and Chief Scientist, CollabRx, Inc
A new paradigm for translational research will be described that combines the integrative and collaborative power of the Internet with personalized molecular analysis to slash the time and cost of therapy development. The creation of Health Commons involves an open web-based ecosystem of researchers, clinicians, patients, pharma/biotechs, and service/technology providers that can be rapidly mobilized to develop targeted therapies for disease subclasses. This ecosystem will stimulate the same radical increase in efficiency for therapy development that ecommerce brought to business in the 1990s, ushering in a new age of collaborative, personalized medicine where every patient can afford custom therapies and discovery is driven by collectively interpreting the outcomes across all patients.

 

Biography
Jay M. ("Marty") Tenenbaum is the founder and Chairman of CollabRx. Dr. Tenenbaum brings to CollabRx the unique perspective of a world-renowned Internet commerce pioneer and visionary. He was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993) and Internet auction (1993). In 1994, he founded CommerceNet to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. Dr. Tenenbaum joined Commerce One in January 1999, when it acquired Veo Systems. As Chief Scientist, he was instrumental in shaping the company's business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon's new West Coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.

 

 

7:30 am Tissue Engineering Strategies for Musculoskeletal Regenerative Medicine in Civilian and Military Applications
Michael J. Yaszemski, Ph.D., M.D., Brigadier General, United States Air Force Reserves, Professor, Orthopedic Surgery and Biomedical Engineering, College of Medicine, Mayo Clinic
Tissue regeneration via tissue engineering strategies requires some combination of cells, a scaffold upon which the cells can attach and express their phenotypic function, and signaling molecules to direct the cells down the desired differentiation path. This cellular component often includes stem cells. This lecture will present current concepts regarding musculoskeletal tissue regeneration and the issues to be considered for its translation to clinical practice, as well as the unique reconstructive challenges encountered in combat injuries.

 

Biography
Dr. Yaszemski is a Professor of Orthopedic Surgery and Bioengineering at the Mayo Clinic, a Consultant in the Department of Orthopedic Surgery, the Chair of the Section of Spine Surgery, and the Director of the Tissue Engineering and Biomaterials Laboratory. He received both a bachelors and masters degree in Chemical Engineering from Lehigh University. He received his Doctorate of Medicine degree from Georgetown University and a Ph.D. in Chemical Engineering from MIT. His clinical practice encompasses spinal surgery, with a focus on the resection and reconstruction of spinopelvic tumors. His research interests are in the synthesis and characterization of novel degradable polymers for use in bone, cartilage, and neurologic tissue regeneration, and in the controlled delivery of chemotherapeutic agents to musculoskeletal cancers.

 

1:40 pm Engineering Cells to Death
James A. Wells, Ph.D., Chair, Professor of Pharmaceutical Sciences, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco
Apoptosis, or programmed cell death, represents an ultimate fate decision in cell biology. This process is critical for cellular differentiation and remodeling of tissues, and for anti-viral and anti-tumor defense. The study of apoptotic pathways has important ramifications for determining what is critical for cellular homeostasis, and for the development of potential anti-cancer therapeutics. A distinct molecular feature of apoptosis is the widespread but controlled cellular proteolysis, that is predominantly mediated by eight members of the caspase family of cysteine proteases. These enzymes are like demolition experts that cleave protein targets critical for cellular life. We have designed new enzymes, and antibodies, and small molecules to study and activate individual caspases and the proteins they cleave. For example, a robust proteomic method for global profiling of proteolysis (“degradomics”) in cells has been developed. Key to this is an engineered enzyme, subtiligase, that permits selective labeling and enrichment for the protein N-termini created as a result of proteolysis. Using this approach we have already identified >300 caspase substrates from Jurkat cells that were induced to undergo apoptosis by treatment with the chemotherapeutic agent etoposide. The proteins fall into a wide range of functional classes, and reveal much about the molecular components, logic, and timed sequence of events that drive a cell from life to death. We believe these engineered enzymes and proteomic approaches will be useful for characterizing the proteolysis of apoptosis induced by various agents or in different cell types, and will be generally useful for dissecting protease signaling pathways.

 

Biography
Dr. Wells received a B.A. degree in biochemistry from the University of California, Berkeley, and a Ph.D. degree in biochemistry from Washington State University with Dr. Ralph Yount. His postdoctoral studies were done at Stanford University Medical School, Department of Biochemistry with Dr. George Stark. Dr. Wells was the founding member of the Protein Engineering Department at Genentech, Inc where he worked for 16 years. His research pioneered gain-of-function design for enzymes, hormones, and antibodies as well as developing new technologies for engineering and probing protein function. In 1998, Dr. Wells founded Sunesis Pharmaceuticals where he served as President and Chief Scientific Officer and developed a novel fragment discovery technology known as disulfide trapping or Tethering. In 2005, Dr. Wells joined UCSF as the Harry W. and Diana Hind Distinguished Professor in Pharmaceutical Sciences. He is a joint Professor in the Departments of Cellular & Molecular Pharmacology, and Pharmaceutical Chemistry and Chair of the Department. His current research uses a combination of protein design and small molecule drug discovery to study cellular processes involved in apoptosis and inflammation. Some of his awards include: the Hans Neurath and Aviv Awards given by the Protein Society, the Pfizer Award given by the American Chemical Society, the du Vignead Award given by the Peptide Society, and in 1999 was elected member of the National Academy of Sciences.

 

2:25 pm Brave New Age of Personalized Medicine
David Ewing Duncan, Chief Correspondent, NPR Talk’s “Biotech Nation” and Best Selling Author “Masterminds”
This focus of this presentation will be on "Creative Disruptions", and will demonstrate the walking scientific response to the question: "Can they really do that?" The most important and controversial topics of today’s scientific research will be discussed, from stem cells and synthetic biology, to rising drug prices and reforming the FDA. Recently, there has been attention on science’s most significant story: a species’ potential to self-evolve. As the founder of the independent BioAgenda Institute for Life Science Studies and, more recently, as the founder of the new Center for Life Science Policy at UC Berkeley, the passion for what comes next after new technologies appear will be explored -- what happens in business, politics, science, philosophy, the media, the arts, and to society as a whole.

 

Biography
David Ewing Duncan is an acclaimed author, commentator, essayist, reporter, television and radio correspondent and producer, and the Director of the Center for Life Science Policy at UC Berkeley. He is a commentator on NPR’s Morning Edition and a former special correspondent and producer for ABC Nightline, He recently became a Contributing Editor and Columnist (“Natural Selection”) for Condé Nast Portfolio. He is the author of the international bestseller “Calendar: Humanity’s Epic Struggle to Determine a True and Accurate Year” (HarperCollins/Avon), published in 19 languages, and a bestseller in 14 countries.

 

His 2006 book, “Masterminds: Genius, DNA and the Quest to Rewrite Life” (Harper Perennial), focuses on the particular motives of scientists: Did the scientist credited for sequencing the human genome have a familial attachment to the issue? Were money and fame an aid to his ambition? Duncan entertains the reader with not just the “how” but also the “why.” A profiler of the world’s most prominent and influential researchers and geneticists, his approach is unique in that he profiles not just the science but also the individuals behind the discoveries.

 

Sponsorships allow you to achieve your objectives before, during and long after the event. Any sponsorship can be customized to meet with your company's needs and budget. Signing on earlier will allow you to maximize exposure to hard-to-reach decision-makers.

 

Podium Presentations

Present your solutions for 15 or 30 minutes in the session room during lunch or as part of the conference program.

Invitation-Only Networking Functions

 

 

- Conference Tote Bags

- Badge Lanyards

- Program Guide Event Directory Sponsorship

- Poster Award Sponsorship

- Corporate Branding Packages

- Tote Bag Inserts

- Refreshment Breaks

- Poster Abstract Book

 - And more!